EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics

Vernise J T Lim, Melanie J Murphy, W Stephen Penrose, Coral Warr, M Cristina Keightley iD, Jacqueline M Orian iD

Animal Models and Experimental Medicine · 2025

DOI: 10.1002/ame2.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Vernise J T Lim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rural Clinical Sciences and Holsworth Biomedical Research Centre, La Trobe University, Bendigo, Australia. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Fingolimod Hydrochloride, Multiple Sclerosis, Immunosuppressive Agents. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Private Donation, La Trobe Research Focus Areas, Multiple Sclerosis Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), exhibiting hallmarks of both inflammation and neurodegeneration and with limited treatment options. The intricate nature of MS pathophysiology and its variable progression pose severe challenges for the development of effective therapies. The experimental autoimmune encephalomyelitis (EAE) MS model, in its most common form, is an aggressive disease, which is not representative of the MS course and offers a limited time window for drug evaluation. This study aimed to generate an attenuated EAE variant, which extends the clinical testing window while preserving the high incidence of the standard EAE model.

Methods

Components of the EAE induction protocol were titrated to develop a milder disease profile. In a subsequent drug trial using the MS medication fingolimod hydrochloride (FTY, Gilenya), the new variant was validated under prophylactic and therapeutic treatment regimens.

Results

The attenuated EAE variant retains the standard hallmarks of neuroinflammation and, crucially, significantly extends the time frame for clinical drug testing. Unlike the standard variant, where FTY efficacy could only be demonstrated by prophylactic treatment, the attenuated variant facilitated differentiation of drug effects by therapeutic treatment initiated early in the acute phase of disease.

Conclusion

The new EAE variant is suitable for use in preclinical assessment of candidate therapeutics and the identification of targetable molecular mechanisms underpinning disease development and progression. This study illustrates the importance of optimizing and refining the experimental tool to enhance the translational success of the candidate therapeutics for MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalFingolimod HydrochlorideMultiple SclerosisImmunosuppressive AgentsAnimalsDisease Models, AnimalFemaleDrug Evaluation, PreclinicalMice, Inbred C57BLMice

Stichwörter der Autor:innen

drug evaluationexperimental autoimmune encephalomyelitisfingolimod hydrochloridemultiple sclerosismultiple sclerosis therapeuticpreclinical drug evaluation

Substanzen

Fingolimod HydrochlorideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Rural Clinical Sciences and Holsworth Biomedical Research Centre, La Trobe University, Bendigo, Australia.
  • La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia.
  • Department of Psychology, Counselling and Therapy, School of Psychology and Public Health, La Trobe University, Bundoora, Australia.
  • Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, Australia.

ORCID-Profile: M Cristina Keightley, Jacqueline M Orian

Förderung

  • Private Donation
  • La Trobe Research Focus Areas
  • Multiple Sclerosis Australia
  • La Trobe University

Zitieren

APA

Lim, V. J. T., Murphy, M. J., Penrose, W. S., Warr, C., Keightley, M. C., & Orian, J. M. (2025). Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.70071

Vancouver

Lim VJT, Murphy MJ, Penrose WS, Warr C, Keightley MC, Orian JM. Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.70071

BibTeX
@article{Lim2025,
  author = {Lim, Vernise J T and Murphy, Melanie J and Penrose, W Stephen and Warr, Coral and Keightley, M Cristina and Orian, Jacqueline M},
  title = {Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics},
  journal = {Animal Models and Experimental Medicine},
  year = {2025},
  doi = {10.1002/ame2.70071}
}
Kostenlos starten →